Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1952959rdf:typepubmed:Citationlld:pubmed
pubmed-article:1952959lifeskim:mentionsumls-concept:C0023418lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0028210lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0059364lld:lifeskim
pubmed-article:1952959lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:1952959pubmed:issue14lld:pubmed
pubmed-article:1952959pubmed:dateCreated1991-12-11lld:pubmed
pubmed-article:1952959pubmed:abstractTextCytocidal effects of combined use of BH-AC and nitrosourea derivatives (MCNU, and ACNU) were evaluated in vitro against adriamycin-resistant human leukemia cell line (K-562/ADR-I). K-562/ADR-I cells were resistant to six kinds of agents (vindesine, mitoxantrone, aclacinomycin, cisplatin, MCNU, and BH-AC) of 14 agents tested and this cell line proved to be a multi-drug resistant line. Combined use of BH-AC and MCNU did not achieve additive effects on K-562, parent cell line and BH-AC and MCNU were less effective to K-562/ADR-I by single use. However, combination of BH-AC and MCNU showed additive effects. These results supported the evidence that combination of BH-AC with MCNU was effective in patients with multi-drug resistant malignant lymphomas.lld:pubmed
pubmed-article:1952959pubmed:languagejpnlld:pubmed
pubmed-article:1952959pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:citationSubsetIMlld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1952959pubmed:statusMEDLINElld:pubmed
pubmed-article:1952959pubmed:monthNovlld:pubmed
pubmed-article:1952959pubmed:issn0385-0684lld:pubmed
pubmed-article:1952959pubmed:authorpubmed-author:TakagiTTlld:pubmed
pubmed-article:1952959pubmed:authorpubmed-author:MatsuuraYYlld:pubmed
pubmed-article:1952959pubmed:authorpubmed-author:OguroMMlld:pubmed
pubmed-article:1952959pubmed:authorpubmed-author:SakaiCClld:pubmed
pubmed-article:1952959pubmed:issnTypePrintlld:pubmed
pubmed-article:1952959pubmed:volume18lld:pubmed
pubmed-article:1952959pubmed:ownerNLMlld:pubmed
pubmed-article:1952959pubmed:authorsCompleteYlld:pubmed
pubmed-article:1952959pubmed:pagination2403-8lld:pubmed
pubmed-article:1952959pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:meshHeadingpubmed-meshheading:1952959-...lld:pubmed
pubmed-article:1952959pubmed:year1991lld:pubmed
pubmed-article:1952959pubmed:articleTitle[In vitro effect of combined use of BH-AC and nitrosourea derivatives against adriamycin-resistant human leukemia cell line].lld:pubmed
pubmed-article:1952959pubmed:affiliationDivision of Hematology and Chemotherapy, Chiba Cancer Center Hospital, Japan.lld:pubmed
pubmed-article:1952959pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1952959pubmed:publicationTypeEnglish Abstractlld:pubmed